🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought itRead More

Alibaba Health surges 13% on strong FY earnings

Published 28/05/2024, 05:44
© Reuters.
HK50
-
BABA
-
0241
-
9988
-

Investing.com-- Shares of Alibaba Health Information Technology (HK:0241) rose sharply on Tuesday after the firm clocked a sharp jump in its annual earnings on improved margins and strong demand for healthcare services and pharmaceuticals on its platforms. 

The firm, which was acquired by e-commerce giant Alibaba Group (HK:9988) (NYSE:BABA) in 2014, rose as much as 13.7% to HK3.55- a two-month high. It was also the top gainer on the Hang Seng index, which rose 0.6%. 

Alibaba Health’s adjusted net profit for the year to March 31, 2024, surged nearly 91% to 1.44 billion yuan ($200 million).

Revenue rose about 1% to 27.03 billion yuan, as sales appeared to be stagnating after COVID-led demand sparked stellar sales growth over the past three years.

But Alibaba Health benefited from improved margins, especially on its online healthcare services, as well as pharmaceutical sales. 

Merchants on its Tmall Healthcare Platform jumped 28% to over 35,000 merchants, while average revenue per user surged 17% year-on-year. 

Going forward, the firm said that 2024 was likely to be a challenging year on the macro front. But it also flagged plans to lean further into the internet health industry, particularly in setting up cloud infrastructure for Chinese hospitals.

The firm also said it will explore the application of artificial intelligence through “large speech models.” 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.